{
  "id": "606ad4bd94d57fd879000054",
  "type": "summary",
  "question": "Why mothers with a CYP2D6 ultrarapid metabolizer phenotype may expose their infants to risk of adverse events when taking codeine while breastfeeding?",
  "ideal_answer": "Mothers with a CYP2D6 ultrarapid metabolizer phenotype may expose their infants to risk of adverse events when taking codeine while breastfeeding, by producing more of the active metabolite, morphine.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28696420"
  ],
  "snippets": [
    {
      "text": "Mothers with a CYP2D6 ultrarapid metabolizer phenotype may expose their infants to risk of adverse events when taking codeine while breastfeeding, by producing more of the active metabolite, morphine. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28696420",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}